Pedro Henrique S. Marcon

Pedro Henrique S. Marcon

Auto-generated profile, based on publicly available information

Pedro Henrique S. Marcon

Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, 05508-000, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in Applied Organometallic Chemistry
Verified
Journal Article
Closed access
CACarolane M. Almeida
Carolane M. Almeida
PMPedro H. S. Marcon
Pedro H. S. Marcon
Erica Cristina Moreno NascimentoErica Cristina Moreno Nascimento
Erica Cristina Moreno Nascimento
JMJoao B. L. Martins
Joao B. L. Martins
MCMarcio A. S. Chagas
Marcio A. S. Chagas
Claudia Cristina GattoClaudia Cristina Gatto
Claudia Cristina Gatto

11 April 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CFCamila Fabbri
Camila Fabbri
PMPedro Henrique S. Marcon
Pedro Henrique S. Marcon
ASAline de Sousa Santiago
Aline de Sousa Santiago
CSCaroline Conceição Sousa
Caroline Conceição Sousa
HQHelenita Costa Quadros
Helenita Costa Quadros
SLStefanie Costa Pinto Lopes
Stefanie Costa Pinto Lopes
Here, we present the synthesis, characterization, and pharmacological evaluation of ruthenium complexes of broad-spectrum drug Atovaquone (ATV). Structure–activity relationships revealed key determinants for antiplasmodial activity, such as the importance of the oxidation state [Ru(III) versus Ru(II)] and of hydrophilic or lipophilic coligands. These complexes demonstrated broader activity against both asexual and sexual parasite stages than ATV. Due to this broader effect, complexes exhibited faster action in antiplasmodial activity than ATV. Ruthenium content from the complexes’ treatment gradually and selectively accumulates in the parasite cell milieu. Efficacy was assessed in vivo against asexual and sexual stages. Complexes were capable of blocking parasite transmission from humans to insects, and this was achieved for both gametocytes and oocyst stages, while ATV solely blocked oocysts. This is the first example of metal complexes inhibiting both asexual and sexual parasites with similar potency, broadly expanding the therapeutic utility of metalladrugs in medicinal chemistry.

14 April 2026 in RSC Advances
Verified
Journal Article
Open access
PDF file
JDJocely L. Dutra
Jocely L. Dutra
PMPedro H. S. Marcon
Pedro H. S. Marcon
GMGustavo Moselli
Gustavo Moselli
FNFabiano M. Niquini
Fabiano M. Niquini
JCJoão Victor F. da Costa
João Victor F. da Costa
JAJOAO HONORATO DE ARAUJO-NETO
JOAO HONORATO DE ARAUJO-NETO
This work describes the synthesis of six new ruthenium(II) complexes bearing para-substituted benzoic acids of general formula [Ru(L)(dppb)(bipy)]PF6, where L = terephthalic acid (L-CO2H), 4-(chloromethyl)benzoic acid (L-CCl), 4-(bromomethyl)benzoic acid (L-CBr), 4-(amino)benzoic acid (L-NH2), and 4-(nitro)benzoic acid (L-NO2), bipy = 2,2′-bipyridine and dppb = 1,4-bis(diphenylphosphino)butane. The complexes were characterized by elemental analysis, molar conductivity, NMR, cyclic voltammetry, IR spectroscopy and, for selected compounds, single-crystal X-ray diffraction. The binuclear complex RuBi exhibited a differentiated structural and spectroscopic pattern, including solvent-dependent 31P NMR signal duplication associated with the coexistence of closely related conformers, as supported by DFT calculations. Electrochemical investigations revealed Ru2+/Ru3+ redox couples whose E1/2 values strongly depend on the electronic nature of the para substituent, following the trend NO2 > COOH > CH2Br ≈ CH2Cl > NH2. The strongly electron-donating –NH2 group significantly lowers the oxidation potential and introduces an additional ligand-centered oxidation process, highlighting the pronounced electronic modulation imposed by this substituent. The in vitro cytotoxicity of the complexes, free ligands, and cisplatin was evaluated against MDA-MB-231 (breast), A549 (lung), A2780 (ovarian), A2780cis (cisplatin-resistant ovarian), and MRC-5 (non-tumor lung) cell lines using the MTT assay. All ruthenium complexes were more cytotoxic than the corresponding free ligands and cisplatin. Among them, [Ru(L-NH2)(dppb)(bipy)]PF6 (RuNH2) stood out, exhibiting a submicromolar IC50 value (0.5 ± 0.1 µM) against A2780 cells and the highest selectivity index (3.6) of the series. Its superior performance can be correlated with the strong donor character of the –NH2 group, which modulates the redox properties of the metal center and enhances hydrogen-bonding capability, potentially favoring stronger biological interactions. RuNH2 was further investigated in advanced biological assays, showing pronounced morphological alterations, significant reduction in clonogenic survival of A2780 cells, and concentration-dependent accumulation in the sub-G1 phase, consistent with induction of cell death. Finally, all complexes, except RuNH2 due to its intrinsic fluorescence, were evaluated for interaction with human serum albumin, revealing moderate binding affinities compatible with bloodstream transport. Collectively, these findings demonstrate how subtle electronic effects govern redox behavior and cytotoxic performance, highlighting RuNH2 as a promising candidate for ovarian cancer therapy.